抗菌薬耐性診断市場の2030年までの予測：病原体別、技術別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の抗菌薬耐性診断市場は2023年に47億6,000万米ドルを占め、2030年には95億8,000万米ドルに達すると予測され、予測期間中のCAGRは10.5％です。

微生物における抗菌薬耐性（AMR）の存在を発見・立証するために使用される診断テストや機器の市場は、"抗菌薬耐性診断市場"と呼ばれています。細菌、ウイルス、真菌、寄生虫を含む微生物が抗菌薬の効果に耐える能力を発達させた結果、感染症治療における有効性が低下または消失し、抗菌薬耐性は世界的に公衆衛生上の大きな懸念となっています。

米国薬局方条約によれば、AMRは全世界で毎年約70万人の死亡を引き起こしています。さらに、微生物感染症の診断と治療が適切に管理されなければ、その数は2050年までに毎年1,000万人に達する可能性があります。

取り組みと意識の向上

医療従事者、立法者、一般市民の間で抗生物質耐性の影響に関する知識が広まったことで、この問題への対策に向けた取り組みが増加しました。さらに、政府、団体、規制当局は、抗生物質の責任ある使用を奨励するキャンペーンを開始し、耐性と闘うための診断ツールの作成と受け入れも開始しました。

高価な診断法と限られた償還政策

最先端の抗菌薬耐性診断検査の中には高価なものもあり、特に資源が乏しい地域では、検査へのアクセスや使用が制限されることがあります。特にヘルスケア資源が乏しい地域では、診断検査の高価格が市場拡大の障害となる可能性があります。しかし、抗菌薬耐性診断薬は、地域やヘルスケアシステムによって異なる政策のもとで保険適用され、償還される可能性があります。特定の検査に対する支払いが不十分であったり、保険が適用されなかったりすることで、その普及と市場拡大が妨げられる可能性があります。

技術開発、ガイドライン、規制への対応

分子診断や次世代シーケンシングなどの分野における診断技術の進歩により、抗生物質耐性の検査能力は向上しています。これらの技術革新は、耐性マーカーをより迅速かつ正確に検出することを可能にし、医療専門家が効果的な治療法を決定する力を与えています。さらに、抗生物質耐性の重要性は規制機関やヘルスケア団体によって認識されており、これらの団体はその使用を促進するための勧告やガイドラインを発表しています。これらの規制は、診断薬の普及を促進すると同時に、市場拡大に必要な規制環境を支えています。

不十分なインフラと専門知識、複雑な規制手続き

抗菌薬耐性検査に関する知識不足のため、地域によってはその潜在能力を十分に発揮できない場合があります。不十分なヘルスケア・インフラや検査スペースの不足も、最新の診断薬の使用を妨げ、市場の拡大を抑制する可能性があります。しかし、抗生物質耐性の新規診断検査について規制当局の承認を得るには時間がかかり、困難が伴うかもしれないです。新規診断薬のイントロダクションは、厳しい規制によって妨げられ、製品の発売が遅れることも多いです。

COVID-19の影響：

COVID-19のパンデミックの結果、ヘルスケアにおける優先順位は劇的に変化し、ウイルスの蔓延を管理し食い止めることに重点が置かれるようになっています。COVID-19の検査と治療（検査室の能力と人員を含む）に資源が振り向けられました。この分野における抗菌薬耐性診断と研究への集中は、このリソースの再配置によって一時的に妨げられたかもしれないです。COVID-19患者では二次的な細菌感染の可能性があるため、COVID-19パンデミックは抗生物質の使用を増加させる結果となっています。

メチシリン耐性黄色ブドウ球菌セグメントは予測期間中最大になると予想される

メチシリン耐性黄色ブドウ球菌セグメントは予測期間中最大のシェアを占めました。このセグメントの成長の主な原因は、病院環境におけるMRSAの有病率の上昇です。例えば、CDCの報告によると、鼻に黄色ブドウ球菌が付着している人の約100人に2人がMRSAを発症しています。この割合は人口のおよそ33％です。さらに、このセグメントの成長に影響を与えるもう1つの要素は、MRSAを特定するための診断検査に対する規制当局の承認が増加していることです。

予測期間中にCAGRが最も高くなると予想されるのは病院セグメントです。

院内感染率の上昇、高率のAMR感染による入院の急増、入院期間の長期化、最先端の診断技術へのアクセスの拡大、手ごろな価格、医療保障の充実などの理由から、病院分野は予測期間中に収益性の高い成長を遂げると予測されます。さらに、MRSA、CDI、DRSPなどの病原体感染は、肺炎、敗血症、血流感染、手術部位感染などを引き起こす可能性があります。従って、病院における病原体に焦点を当てた疾患の流行も、このセグメントの成長に寄与しています。

最もシェアの高い地域：

AMR発症のリスクが高いこと、政府のAMR規制があること、医療インフラが進んでいることから、予測期間中、北米が最大のシェアを占めています。さらに、主要市場参入企業の存在と戦略的イニシアティブにより、今後数年間は地域拡大が促進されると予測されます。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域は最も急速な拡大が見込まれます。抗生物質耐性の頻度の高さ、手頃な価格の診断ソリューションに対する需要の増加、未開拓の市場ポテンシャルの存在などが、この地域の成長に寄与しています。加えて、同地域の拡大には、対象となる人口が多いこと、老年人口が増加していること、政府主催の啓発キャンペーンが数多く実施されていることも寄与していると予想されます。さらに、改良された診断ソリューションの創出に関連する研究開発努力の成長が、同地域の拡大を後押しすると予想されます。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 技術分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の抗菌薬耐性診断市場：病原体別

• 薬剤耐性連鎖球菌
• 薬剤耐性肺炎球菌（DRSP）
• メチシリン耐性黄色ブドウ球菌
• クロストリジウム・ディフィシル（CD）
• 薬剤耐性淋菌（DRNG）
• 薬剤耐性サルモネラ菌（DRNTS）
• その他の病原体

第6章 世界の抗菌剤耐性診断市場：技術別

• 免疫測定法
• 微生物培養
• 質量分析法
• 迅速かつポイントオブケア
• その他の技術

第7章 世界の抗菌剤耐性診断市場：エンドユーザー別

• 製薬およびバイオテクノロジー企業
• 診断研究所
• 病院
• その他のエンドユーザー

第8章 世界の抗菌剤耐性診断市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Abbott Laboratories
• Accelerate Diagnostics, Inc.
• Becton, Dickinson and Company
• Biomerieux
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Molsid
• OpGen
• Vela Diagnostics
• Visby Medical, Inc.

List of Tables

• Table 1 Global Antimicrobial Resistance Diagnostic Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
• Table 3 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
• Table 4 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
• Table 5 Global Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
• Table 6 Global Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
• Table 7 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
• Table 8 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
• Table 9 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
• Table 10 Global Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
• Table 11 Global Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 12 Global Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
• Table 13 Global Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
• Table 14 Global Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
• Table 15 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 16 Global Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
• Table 17 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 18 Global Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 19 Global Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 20 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 21 North America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
• Table 22 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
• Table 23 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
• Table 24 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
• Table 25 North America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
• Table 26 North America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
• Table 27 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
• Table 28 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
• Table 29 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
• Table 30 North America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
• Table 31 North America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 32 North America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
• Table 33 North America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
• Table 34 North America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
• Table 35 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 36 North America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
• Table 37 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 38 North America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 39 North America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 40 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 41 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
• Table 42 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
• Table 43 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
• Table 44 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
• Table 45 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
• Table 46 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
• Table 47 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
• Table 48 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
• Table 49 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
• Table 50 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
• Table 51 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 52 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
• Table 53 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
• Table 54 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
• Table 55 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 56 Europe Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
• Table 57 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 58 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 59 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 60 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 61 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
• Table 62 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
• Table 63 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
• Table 64 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
• Table 65 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
• Table 66 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
• Table 67 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
• Table 68 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
• Table 69 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
• Table 70 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
• Table 71 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 72 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
• Table 73 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
• Table 74 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
• Table 75 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 76 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
• Table 77 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 78 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 79 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 80 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 81 South America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
• Table 82 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
• Table 83 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
• Table 84 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
• Table 85 South America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
• Table 86 South America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
• Table 87 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
• Table 88 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
• Table 89 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
• Table 90 South America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
• Table 91 South America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 92 South America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
• Table 93 South America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
• Table 94 South America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
• Table 95 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 96 South America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
• Table 97 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 98 South America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 99 South America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 100 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 101 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
• Table 102 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
• Table 103 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
• Table 104 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
• Table 105 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
• Table 106 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
• Table 107 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
• Table 108 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
• Table 109 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
• Table 110 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
• Table 111 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 112 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
• Table 113 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
• Table 114 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
• Table 115 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 116 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
• Table 117 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 118 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 119 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 120 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Antimicrobial Resistance Diagnostic Market is accounted for $4.76 billion in 2023 and is expected to reach $9.58 billion by 2030 growing at a CAGR of 10.5% during the forecast period. The market for diagnostic tests and instruments used to find and establish the presence of antimicrobial resistance (AMR) in microorganisms is referred to as the "antimicrobial resistance diagnostic market." As a result of the development of the ability of microorganisms, including bacteria, viruses, fungi, and parasites, to withstand the effects of antimicrobial medications, which reduces or eliminates their effectiveness in treating infections, antimicrobial resistance is a major public health concern worldwide.

According to the United States Pharmacopeial Convention, AMR caused about 700,000 deaths globally every year. Moreover, the number can reach 10 million each year by 2050, if diagnosis and treatment of microbial infections are not managed properly.

Market Dynamics:

Driver:

Increasing initiatives and awareness

Increased initiatives aimed at combating the problem were made possible by the growing knowledge of the effects of antibiotic resistance among healthcare professionals, legislators, and the general public. Furthermore, governments, organizations, and regulatory authorities have started campaigns to encourage the responsible use of antibiotics as well as the creation and acceptance of diagnostic tools to combat resistance.

Restraint:

Expensive diagnostic procedures and policies for limited reimbursement

Some cutting-edge antimicrobial resistance diagnostic tests can be expensive, which restricts access to and use of them, particularly in places with low resources. The high price of diagnostic tests may be an obstacle to market expansion, especially in areas with constrained healthcare resources. However, antimicrobial resistance diagnostics may be covered and reimbursed under different policies, depending on the region and healthcare system. Their uptake and market expansion may be hampered by inadequate payment or a lack of insurance coverage for certain tests.

Opportunity:

Technological developments and guidelines and support for regulations

Diagnostic technology advancements in areas like molecular diagnostics and next-generation sequencing have improved the capability of tests for antibiotic resistance. These innovations allow for the quicker and more precise detection of resistance markers, empowering medical professionals to determine effective treatments. Additionally, the importance of antibiotic resistance has been acknowledged by regulatory bodies and healthcare organizations, which have released recommendations and guidelines to promote their usage. These regulations support the regulatory environment needed for market expansion while facilitating the uptake of diagnostics.

Threat:

Inadequate infrastructure and expertise and complex regulatory procedures

Antimicrobial resistance tests may not be used to their full potential in some areas due to a lack of knowledge about them. Inadequate healthcare infrastructure and a lack of laboratory space might also prevent the use of modern diagnostics and restrain market expansion. However, it might take a while and be difficult to get regulatory approval for novel diagnostic tests for antibiotic resistance. The introduction of novel diagnostics might be hampered by strict regulatory regulations, which can often delay the launch of products.

COVID-19 Impact:

Priorities in healthcare have dramatically changed as a result of the COVID-19 pandemic to focus on managing and containing the virus's spread. Resources have been redirected toward COVID-19 testing and treatment, including laboratory capacity and manpower. The concentration on antimicrobial resistance diagnostics and research efforts in this area may have been momentarily hampered by this resource relocation. Due to the possibility of secondary bacterial infections in COVID-19 patients, the COVID-19 pandemic has resulted in an increase in the use of antibiotics.

The methicillin resistant staphylococcus aureus segment is expected to be the largest during the forecast period

Methicillin Resistant Staphylococcus Aureus segment commanded the largest share over the forecast period. The main cause of the segment's growth is the rising prevalence of MRSA in hospital settings. For instance, the CDC reports that approximately two in every 100 of those with S. aureus on their noses develop MRSA. This percentage of the population is roughly 33%. Moreover, another element influencing the segment's growth is the rise in regulatory approvals for diagnostic tests for identifying MRSA.

The hospitals segment is expected to have the highest CAGR during the forecast period

Because of the rising rate of hospital-acquired infections, the surge in hospitalizations caused by the high rate of AMR infections, prolonged hospital stays, expanding access to cutting-edge diagnostic technologies, affordability, and better healthcare coverage, the hospital segment is predicted to grow profitably over the forecast period. Additionally, pathogenic infections, including MRSA, CDI, and DRSP, can result in pneumonia, sepsis, bloodstream infections, and surgical site infections. Therefore, the prevalence of pathogen-focused illnesses in hospitals also contributes to segment growth.

Region with largest share:

Due to the high risk of developing AMR, the presence of supportive government AMR regulations, and the region's advanced healthcare infrastructure, North America held the largest percentage over the predicted period. Furthermore, it is anticipated that regional expansion will be fueled in the upcoming years by the existence of major market participants and the strategic initiatives.

Region with highest CAGR:

During the forecast period, Asia-Pacific is expected to experience the most rapid expansion. A high frequency of antibiotic resistance, an increase in the demand for affordable diagnostic solutions, and the presence of unexplored market potential all contribute to the region's growth. Additionally, the region's expansion is also anticipated to be aided by the region's sizable, targeted population, growing geriatric population, and a number of government-sponsored awareness campaigns. Additionally, it is anticipated that growth in R&D efforts connected to the creation of improved diagnostic solutions will support region expansion.

Key players in the market:

Some of the key players in Antimicrobial Resistance Diagnostic market include: Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux , Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Molsid , OpGen, Vela Diagnostics and Visby Medical, Inc..

Key Developments:

In November 2022, Danaher Corporation came into partnership with Duke University, a research University. Under this partnership, Danaher Corporation aimed to shape Danaher Beacon for the development of Gene Therapy Innovation.

In August 2022, Becton, Dickinson, and Company entered into collaboration with Accelerate Diagnostics, Inc., a developer of rapid in-vitro diagnostics in microbiology. This Collaboration would enable the former company to help clinicians treat patients in a Constructive and organized way resulting in a decrease in costs in healthcare and helping restrict the stretch of antimicrobial resistance.

Pathogens Covered:

• Drug Resistant Streptococcus
• Drug Resistant Streptococcus Pneumoniae (DRSP)
• Methicillin Resistant Staphylococcus Aureus
• Clostridium Difficile (CD)
• Drug Resistant Neisseria Gonorrhoeae (DRNG)
• Drug Resistant Salmonella (DRNTS)
• Other Pathogens

Technologies Covered:

• Immunoassay
• Microbiology Culture
• Mass Spectrometry
• Rapid & Point of Care
• Other Technologies

End Users Covered:

• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Antimicrobial Resistance Diagnostic Market, By Pathogen

• 5.1 Introduction
• 5.2 Drug Resistant Streptococcus
• 5.3 Drug Resistant Streptococcus Pneumoniae (DRSP)
• 5.4 Methicillin Resistant Staphylococcus Aureus
• 5.5 Clostridium Difficile (CD)
• 5.6 Drug Resistant Neisseria Gonorrhoeae (DRNG)
• 5.7 Drug Resistant Salmonella (DRNTS)
• 5.8 Other Pathogens

6 Global Antimicrobial Resistance Diagnostic Market, By Technology

• 6.1 Introduction
• 6.2 Immunoassay
• 6.3 Microbiology Culture
• 6.4 Mass Spectrometry
• 6.5 Rapid & Point of Care
• 6.6 Other Technologies

7 Global Antimicrobial Resistance Diagnostic Market, By End User

• 7.1 Introduction
• 7.2 Pharmaceutical & Biotechnology Companies
• 7.3 Diagnostic Laboratories
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Antimicrobial Resistance Diagnostic Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Accelerate Diagnostics, Inc.
• 10.3 Becton, Dickinson and Company
• 10.4 Biomerieux
• 10.5 Danaher Corporation
• 10.6 F. Hoffmann-La Roche Ltd.
• 10.7 Hologic, Inc.
• 10.8 Molsid
• 10.9 OpGen
• 10.10 Vela Diagnostics
• 10.11 Visby Medical, Inc.